Lansoprazole Inhibits Nitric Oxide and Prostaglandin E2 Production in Murine Macrophage RAW 264.7 Cells

详细信息    查看全文

• 作者：Shuji Nakagawa (1)
  Yuji Arai (1) yarai89046@nike.eonet.ne.jp
  Tsunao Kishida (2)
  Nobuyuki Hiraoka (1)
  Shinji Tsuchida (1)
  Hiroaki Inoue (1)
  Ryo Sakai (1)
  Osam Mazda (2)
  Toshikazu Kubo (1)
• 关键词：KEY WORDS lansoprazole &#8211 ; macrophage &#8211 ; nitric oxide &#8211 ; prostaglandin E2 &#8211 ; NADPH oxidase
• 刊名：Inflammation
• 出版年：2012
• 出版时间：June 2012
• 年：2012
• 卷：35
• 期：3
• 页码：1062-1068
• 全文大小：197.8 KB
• 参考文献：1. Biswas, K., U. Bandyopadhyay, I. Chattopadhyay, A. Varadaraj, E. Ali, and R.K. Banerjee. 2003. A novel antioxidant and antiapoptotic role of omeprazole to block gastric ulcer through scavenging of hydroxyl radical. Journal of Biological Chemistry 278(13): 10993–11001.
  2. Yoshida, N., T. Yoshikawa, Y. Tanaka, N. Fujita, K. Kassai, Y. Naito, and M. Kondo. 2000. A new mechanism for anti-inflammatory actions of proton pump inhibitors—inhibitory effects on neutrophil–endothelial cell interactions. Alimentary Pharmacology & Therapeutics 14(Suppl 1): 74–81.
  3. Dickinson, J.B. 1994. Is omeprazole helpful in inflammatory bowel disease? Journal of Clinical Gastroenterology 18(4): 317–319.
  4. Elliott, M.J., R.N. Maini, M. Feldmann, A. Long-Fox, P. Charles, H. Bijl, and J.N. Woody. 1994. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344(8930): 1125–1127.
  5. Ikeda, U., and K. Shimada. 1999. Statins and monocytes. Lancet 353(9169): 2070.
  6. Kim, J.K., S.M. Oh, H.S. Kwon, Y.S. Oh, S.S. Lim, and H.K. Shin. 2006. Anti-inflammatory effect of roasted licorice extracts on lipopolysaccharide-induced inflammatory responses in murine macrophages. Biochemical and Biophysical Research Communications 345(3): 1215–1223.
  7. Sakao, K., K.A. Takahashi, O. Mazda, Y. Arai, H. Tonomura, A. Inoue, M. Saito, M. Fujioka, H. Takamiya, J. Imanishi, and T. Kubo. 2008. Enhanced expression of interleukin-6, matrix metalloproteinase-13, and receptor activator of NF-kappaB ligand in cells derived from osteoarthritic subchondral bone. Journal of Orthopaedic Science 13(3): 202–210.
  8. Li, J.M., N.P. Gall, D.J. Grieve, M. Chen, and A.M. Shah. 2002. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 40(4): 477–484.
  9. Blandizzi, C., G. Natale, G. Gherardi, G. Lazzeri, C. Marveggio, R. Colucci, D. Carignani, and M. Del Tacca. 1999. Acid-independent gastroprotective effects of lansoprazole in experimental mucosal injury. Digestive Diseases and Sciences 44(10): 2039–2050.
  10. Nakamura, M., M. Asada, K. Atsuda, H. Matsui, T. Watanabe, K. Higuchi, T. Arakawa, N. Hibi, and K. Tsuchimoto. 2005. Lansoprazole binding to the neutrophils in dextran sulfate sodium-induced rat colitis. Inflammopharmacology 13(1–3): 303–315.
  11. Hinoki, A., K. Yoshimura, K. Fujita, M. Akita, R. Ikeda, M. Nagashima, M. Nomura, and A. Satomi. 2006. Suppression of proinflammatory cytokine production in macrophages by lansoprazole. Pediatric Surgery International 22(11): 915–923.
  12. Harris, S.G., J. Padilla, L. Koumas, D. Ray, and R.P. Phipps. 2002. Prostaglandins as modulators of immunity. Trends in Immunology 23(3): 144–150.
  13. Lee, T.Y., K.C. Lee, S.Y. Chen, and H.H. Chang. 2009. 6-Gingerol inhibits ROS and iNOS through the suppression of PKC-alpha and NF-kappaB pathways in lipopolysaccharide-stimulated mouse macrophages. Biochemical and Biophysical Research Communications 382(1): 134–139.
  14. Adams, D.O., and T.A. Hamilton. 1984. The cell biology of macrophage activation. Annual Review of Immunology 2: 283–318.
  15. Sarna, L.K., N. Wu, S.Y. Hwang, Y.L. Siow, and O. Karmin. 2010. Berberine inhibits NADPH oxidase mediated superoxide anion production in macrophages. Canadian Journal of Physiology and Pharmacology 88(3): 369–378.
  16. Sadowska, A.M., B. Manuel-Y-Keenoy, and W.A. De Backer. 2007. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulmonary Pharmacology and Therapeutics 20(1): 9–22.
• 作者单位：1. Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566 Japan2. Department of Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566 Japan
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Rheumatology
  Internal Medicine
  Pharmacology and Toxicology
  Pathology
  
• 出版者：Springer Netherlands
• ISSN：1573-2576

文摘

Aberrantly activated macrophages, which overproduce inflammatory mediators, are involved in the pathogenesis of many inflammatory diseases. We analyzed the anti-inflammatory activity of lansoprazole (LPZ), a typical proton pump (P-ATPase) inhibitor, on RAW264.7 murine macrophages. Treatment of lipopolysaccharide (LPS)-stimulated RAW264.7 cells with LPZ inhibited the production of nitric oxide (NO) and prostaglandin E₂ (PGE₂). Since P-ATPase expression was not observed in RAW264.7 cells, the anti-inflammatory effect of LPZ was independent of ATPase. In contrast, diphenylene iodonium (DPI), an inhibitor of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, decreased NO but not PGE₂ levels. LPZ suppressed the LPS-stimulated production by RAW264.7 cells of reactive oxygen species (ROS), which plays an important role in inflammatory responses. ROS elevation in these cells was associated with NO but not PGE₂ production, suggesting that LPZ inhibits NO production by suppressing NADPH oxidase activity. These findings suggest that LPZ may be useful in the treatment of many inflammatory diseases associated with activated macrophages.